- Home
- INVH vs RPRX Comparison
INVH vs RPRX Comparison
Compare INVH & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INVH | RPRX |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5B | 16.4B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INVH | RPRX |
|---|---|---|
| Price | $27.62 | $39.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 4 |
| Target Price | $34.53 | ★ $45.75 |
| AVG Volume (30 Days) | ★ 7.0M | 3.3M |
| Earning Date | 02-25-2026 | 02-10-2026 |
| Dividend Yield | ★ 4.43% | 2.37% |
| EPS Growth | ★ 32.35 | N/A |
| EPS | 0.95 | ★ 1.75 |
| Revenue | ★ $2,689,621,000.00 | $2,349,844,000.00 |
| Revenue This Year | $5.81 | $37.66 |
| Revenue Next Year | $3.17 | $2.34 |
| P/E Ratio | $28.48 | ★ $22.68 |
| Revenue Growth | ★ 5.29 | 3.70 |
| 52 Week Low | $25.29 | $29.66 |
| 52 Week High | $35.80 | $41.70 |
Technical Indicators
Market Signals| Indicator | INVH | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 49.50 |
| Support Level | $25.98 | $39.87 |
| Resistance Level | $26.95 | $40.58 |
| Average True Range (ATR) | 0.71 | 0.78 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 74.14 | 34.46 |
Price Performance
Historical ComparisonAbout INVH Invitation Homes Inc.
Invitation Homes owns a portfolio of over 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 17 target markets that feature high employment and household formation growth with over 70% of the portfolio in the Western US and Florida; 15 of the 17 markets featuring average rents lower than homeownership costs.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.